Targeting MOR-mGluR(5) heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5

Pain is among the most common symptoms in cancer and approximately 90% of patients experience end-stage cancer pain. The management of cancer pain is challenging due to the significant side effects associated with opioids, and novel therapeutic approaches are needed. MMG22 is a bivalent ligand conta...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology
Main Authors: Shueb, Sarah S., Erb, Samuel J., Lunzer, Mary M., Speltz, Rebecca, Harding-Rose, Catherine, Akgün, Eyup, Simone, Donald A., Portoghese, Philip S.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7210724/
https://ncbi.nlm.nih.gov/pubmed/31271770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2019.107690
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items